03 Profile
Hansard to 4 November 2026 · 31,174 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Mike Davis
Acting Director, Center for Drug Evaluation and Research
press citation on 1 topic since 18 Jun 2026 · last quoted 18 Jun 2026
02 Quoted on · 1 of 29 topics
Mike Davis: key facts
- Kind of voice
- Sector leader
- Role
- Acting Director, Center for Drug Evaluation and Research
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 18 Jun 2026
04 The signal · where Mike Davis sits on rare diseases
Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
- 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
- 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
- 25=Ann NordgrenClinicianprofessor of clinical genetics at the Karolinska Institutet and senior consultant at Karolinska University Hospital1
- 25=Karim MikhailSector leaderActing Director, Center for Biologics Evaluation and Research1
- 25=Mike DavisSector leaderActing Director, Center for Drug Evaluation and Research1
- 25=Elena MaksimkinaSector leaderhead of the Federal Center for Drug Planning and Provision (FCDPiLO)1
- 25=Alexander Hoischen, PhDAcademicprofessor of genomic technologies at Radboud University Medical Center1
Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →
05 On the record · press
What Mike Davis has said
- fda.gov1
Where Mike Davis has been quoted
- 01Lessons Learned from our Roundtable with Rare Disease Advocatesfda.gov · 18 Jun 2026
Verbatim
“What we need to champion, and what we discussed at length with the advocates, is a tailored regulatory approach to drugs that treat rare diseases.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.